| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine (IM) Oxcarbazepine | Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Decreased rilpivirine effects |
Use alternative agents |
|||
| Lenacapavir Oxcarbazepine | Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Potential loss of antiviral efficacy |
Use alternative agents |
|||
| Darunavir Oxcarbazepine 979 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential loss of antiviral efficacy |
Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended |
|||
| Tenofovir alafenamide Oxcarbazepine 719 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of TAF | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Rilpivirine Oxcarbazepine 659 | Red: Avoid combination | Contraindicated | |||||
| Doravirine Oxcarbazepine 350 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of doravirine | Potential decrease in antiretroviral efficacy |
Contraindicated. Use alternative agents. If discontinuing oxcarbazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine. |
|||
| Cabotegravir Oxcarbazepine 336 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of CAB | Potential decrease in antiretroviral efficacy |
Not studied |
Not studied |
Contraindicated. Use alternative agents. |
|
| Raltegravir Oxcarbazepine 324 | Orange: Minimal data to guide interaction | Do not coadminister: Potential for reduced levels of raltegravir | Potential decrease in antiretroviral efficacy |
Consider using alternative agents |
|||
| Elvitegravir Oxcarbazepine 229 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Dolutegravir Oxcarbazepine 116 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of dolutegravir | Potential decrease in antiretroviral efficacy |
Not studied (may decreased dolutegravir levels) |
Not studied |
Avoid combination or use alternative agents |
|
| Bictegravir Oxcarbazepine 78 | Red: Avoid combination | Do not coadminister: Potential for reduced levels of BIC and TAF | Potential decrease in antiretroviral efficacy |
Use alternative agents |
|||
| Maraviroc Oxcarbazepine 62 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential decrease in antiretroviral efficacy |
Use alternative agents |
